Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report [0.03%]
blastic浆细胞样树突细胞肿瘤患者在接受Tagraxofusp治疗后发生足坏死:病例报告
Jad Sibai,RuiQi Chen,Ibrahim Al Nabhani et al.
Jad Sibai et al.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy. It is associated with poor prognosis and heterogenous presentation. The CD123-directed cytotoxin, Tagraxofusp, is a targeted therapy for B...
Case Reports
EJHaem. 2022 Aug 4;3(4):1374-1376. DOI:10.1002/jha2.541 2022
Chea Mathias,Brun Sophie,Loyens Maxime
Chea Mathias
Lower-risk myelodysplastic syndromes: Current treatment options for anemia [0.03%]
低危骨髓增生异常综合征贫血的现有治疗选择
Mathieu Meunier,Sophie Park
Mathieu Meunier
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematological disorders. Treatment options are classified and defined by prognostic risk based on the International Prognostic Scoring System (IPSS) and, more recently, the...
COVID-19 infection and pain in adolescents with sickle cell disease: A case series [0.03%]
青少年镰状细胞疾病患者中COVID-19感染与疼痛:病例系列报告
Heidi M Heyman,Nicole M Alberts,Matthew Rees et al.
Heidi M Heyman et al.
Adolescents with sickle cell disease (SCD) have been shown to have pain-related sequelae following COVID-19 infection. In this case series, we discuss five adolescents with SCD and SARS-CoV-2 infection who subsequently developed complex pai...
Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis [0.03%]
口服JAK2/IRAK1抑制剂pacritinib在骨纤维化患者中的风险调整安全性分析
Naveen Pemmaraju,Claire Harrison,Vikas Gupta et al.
Naveen Pemmaraju et al.
The safety profile of the novel oral JAK2/IRAK1 inhibitor pacritinib in patients with cytopenic myelofibrosis was described in the Phase 2 PAC203 and Phase 3 PERSIST-2 studies. To account for longer treatment durations on the pacritinib arm...
De-escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open-label, prospective trial in China [0.03%]
慢粒患者酪氨酸激酶抑制剂降阶或者停药的多中心开放标签前瞻性研究
Jie Luo,Xin Du,Jin Lou et al.
Jie Luo et al.
Background: Long-term treatment-free remission (TFR) represents a new goal for chronic myeloid leukemia (CML). Optimizing dose of tyrosine kinase inhibitors (TKIs) in the CML treatment maybe a new challenge to maintain effective and improvi...
Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non-germinal centre B-cell-like diffuse large B-cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial [0.03%]
伊布替尼联合利妥昔单抗和环磷酰胺、多柔比星、长春新碱及强的松治疗未经治疗的非生发中心B细胞样弥漫性大B细胞淋巴瘤的中国亚组分析:III期PHOENIX试验
Jun Zhu,Xiaonan Hong,Yu Qin Song et al.
Jun Zhu et al.
In this post hoc subgroup analysis of 200 patients enrolled in China from the phase III PHOENIX trial (N = 838, NCT01855750), addition of ibrutinib to rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) did not...
Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide [0.03%]
羟基脲治疗的真性红细胞增多症和原发性血小板增多症患者的皮肤癌发生情况
Abhinav Mathur,Joakim Edman,Livia Liang et al.
Abhinav Mathur et al.
Hydroxycarbamide (HC) is used as a cytoreductive treatment in myeloproliferative neoplasms (MPN). Observational studies have raised the possibility that HC contributes to the development of secondary malignancies, including skin tumours in ...
Establishment and characterization of a new mantle cell lymphoma cell line with a NOTCH2 mutation, Arbo [0.03%]
具有NOTCH2突变的新套细胞瘤细胞系Arbo的建立和特征分析
Firas Safa,Terri Rasmussen,Patricia Lobelle-Rich et al.
Firas Safa et al.
Cell lines represent an essential tool used in preclinical research. Most hematologic malignancies have a wide array of cell lines representing their respective molecular and pathologic spectra. In mantle cell lymphoma (MCL), cell lines bec...
Bradley Steinman,Jose A Plaza,Adam S Kittai
Bradley Steinman